Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | CES2 | O00748 | 1/20 | 0.48 |
| ▸ | CES1 | P23141 | 1/20 | 0.48 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | CTSD | P07339 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.39 |
| ▸ | DRD3 | P35462 | 2/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | EDNRB | P24530 | 1/20 | 0.39 |
| ▸ | MC4R | P32245 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6702874 | 0.81 | CES2 (0.50) | CYP2D6CYP1A2PKMSMN1; SMN2NPSR1 | |
| SCHEMBL777870 | 0.79 | ALDH1A1 (0.55) | CYP2D6CES2CES1SRCLMNA | |
| SCHEMBL6176782 | 0.79 | CES2 (0.48) | CYP2D6CES2CES1SRCLMNA | |
| SCHEMBL5306707 | 0.78 | CYP2D6 (0.52) | CYP2D6CYP1A2PKMSMN1; SMN2NPSR1 | |
| SCHEMBL1955 | 0.78 | ESR1 (0.53) | CYP2D6CYP1A2PKMSMN1; SMN2NPSR1 | |
| SCHEMBL29816355 | 0.78 | CYP2D6 (0.52) | CYP2D6CYP1A2PKMSMN1; SMN2NPSR1 | |
| SCHEMBL28176185 | 0.78 | PARP1 (0.44) | LMNAKMT2A | |
| SCHEMBL9860354 | 0.78 | HCAR2 (0.56) | CYP2D6CES2CES1SRCLMNA | |
| SCHEMBL9860357 | 0.78 | HCAR2 (0.56) | CYP2D6CES2CES1SRCLMNA | |
| SCHEMBL4216010 | 0.78 | TSHR (0.57) | SMN1; SMN2CES2CES1LMNAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 504 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250257031-A1 | PROCESS FOR THE PRODUCTION OF SUBSTITUTED 2-[2-(PHENYL)ETHYLAMINO]ALKANEAMIDE DERIVATIVES | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2025-08-14 | — | — | US | claimed |
| US-12291495-B2 | Process for the production of substituted 2-[2-(phenyl)ethylamino] alkaneamide derivatives | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2025-05-06 | — | — | US | claimed |
| US-20220185766-A1 | PROCESS FOR THE PRODUCTION OF SUBSTITUTED 2-[2-(PHENYL)ETHYLAMINO]ALKANEAMIDE DERIVATIVES | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2022-06-16 | — | — | US | claimed |
| EP-3956296-A1 | PROCESS FOR THE PRODUCTION OF SUBSTITUTED 2-[2-(PHENYL) ETHYLAMINO]ALKANEAMIDE DERIVATIVES | Newron Pharmaceuticals S.p.A. (IT) | 2022-02-23 | — | — | EP | claimed |
| WO-2020212352-A1 | PROCESS FOR THE PRODUCTION OF SUBSTITUTED 2-[2-(PHENYL) ETHYLAMINO]ALKANEAMIDE DERIVATIVES | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2020-10-22 | — | — | WO | claimed |
| EP-3725769-A1 | PROCESS FOR THE PRODUCTION OF SUBSTITUTED 2-[2-(PHENYL) ETHYLAMINO]ALKANEAMIDE DERIVATIVES | Newron Pharmaceuticals S.p.A. (IT) | 2020-10-21 | — | — | EP | claimed |
| WO-2026089784-A2 | COMPOUNDS AND COMPOSITIONS FOR CONJUGATION TO BIOLIGANDS FOR IMAGING AND RADIOPHARMACEUTICAL APPLICATIONS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2026-04-30 | — | — | WO | disclosed |
| US-20250257031-A1 | PROCESS FOR THE PRODUCTION OF SUBSTITUTED 2-[2-(PHENYL)ETHYLAMINO]ALKANEAMIDE DERIVATIVES | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2025-08-14 | — | — | US | disclosed |
| WO-2025151874-A1 | INDOLE ALKALOID ANTIPLASMODIAL AGENTS AND PREPARATION THEREOF | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (US) | 2025-07-17 | — | — | WO | disclosed |
| US-12291495-B2 | Process for the production of substituted 2-[2-(phenyl)ethylamino] alkaneamide derivatives | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2025-05-06 | — | — | US | disclosed |
| WO-2025038960-A1 | OLIGONUCLEOTIDES CONTAINING A LIGAND AT AN INTERNAL POSITION | ADARX PHARMACEUTICALS, INC. (US) | 2025-02-20 | — | — | WO | disclosed |
| EP-4440560-A1 | SMALL MOLECULE INHIBITORS OF REPEAT ASSOCIATED NON-AUG (RAN) TRANSLATION AND COMBINATION THERAPIES | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2024-10-09 | — | — | EP | disclosed |
| US-12083186-B2 | Methods for assembling scavenging particles | NANOTICS, LLC (US) | 2024-09-10 | — | — | US | disclosed |
| WO-2007117639-A2 | SYNTHESIS OF TETRACYCLINES AND ANALOGUES THEREOF | THE PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2007-10-18 | — | — | WO | disclosed |
| CN-101010336-A | Peptide antibiotics and process for preparing same | BIOSOURCE PHARM INC (US) | 2007-08-01 | — | — | CN | disclosed |
| WO-2007013965-A2 | SYNTHESIS OF SCABRONINES AND ANALOGUES THEREOF | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2007-02-01 | — | — | WO | disclosed |
| WO-2006138380-A2 | AMINE-CONTAINING LIPIDS AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2006-12-28 | — | — | WO | disclosed |
| WO-2006124902-A2 | SYNTHESIS OF SALINOSPORAMIDE A AND ANALOGUES THEREOF | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2006-11-23 | — | — | WO | disclosed |
| WO-2006113615-A2 | ANTI-MICROBIAL AGENTS AND USES THEREOF | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2006-10-26 | — | — | WO | disclosed |
| CN-1247535-A | Aminoepoxides from aminoaldehydes and in-situ formed halomethyl organometallic reagent | SEARLE & CO (US) | 2000-03-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220185766-A1 | PROCESS FOR THE PRODUCTION OF SUBSTITUTED 2-[2-(PHENYL)ETHYLAMINO]ALKANEAMIDE DERIVATIVES | HRH3, CYP2A7, HRH4 | CYP2D6 116/4885CYP1A2 233/4885PKM 4267/4885 |
| US-20250257031-A1 | PROCESS FOR THE PRODUCTION OF SUBSTITUTED 2-[2-(PHENYL)ETHYLAMINO]ALKANEAMIDE DERIVATIVES | HRH3, HRH4, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | CYP2D6 56/4885CYP1A2 171/4885PKM 3812/4885 |
| US-12291495-B2 | Process for the production of substituted 2-[2-(phenyl)ethylamino] alkaneamide derivatives | HRH3, CYP2A7, HRH4 | CYP2D6 116/4885CYP1A2 233/4885PKM 4267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.